Nathan Huneke
@nathanhuneke.bsky.social
NIHR Academic Clinical Lecturer in General Adult Psychiatry at the University of Southampton
Placebo Effects | Affective and Anxiety Disorders
nathanhuneke.netlify.app
Placebo Effects | Affective and Anxiety Disorders
nathanhuneke.netlify.app
It was a real privilege to be invited to present on treatment-resistance in anxiety disorders at the Psychiatry Masterclass 2025 at the Conrad Dubai. Many thanks to the organising and scientific committees for inviting me!
It was great to be there with such excellent speakers!
It was great to be there with such excellent speakers!
November 7, 2025 at 7:01 AM
It was a real privilege to be invited to present on treatment-resistance in anxiety disorders at the Psychiatry Masterclass 2025 at the Conrad Dubai. Many thanks to the organising and scientific committees for inviting me!
It was great to be there with such excellent speakers!
It was great to be there with such excellent speakers!
Our new Insights article out now in European Neuropsychopharmacology
We argue that poor control conditions in digital therapeutics trials risk misleading efficacy claims.
Let’s raise the bar for DTx trial design.
🔗 authors.elsevier.com/a/1l-8p,L21E...
@ecnp.eu
#DTx #MentalHealth #ClinicalTrials
We argue that poor control conditions in digital therapeutics trials risk misleading efficacy claims.
Let’s raise the bar for DTx trial design.
🔗 authors.elsevier.com/a/1l-8p,L21E...
@ecnp.eu
#DTx #MentalHealth #ClinicalTrials
October 25, 2025 at 2:55 PM
Our new Insights article out now in European Neuropsychopharmacology
We argue that poor control conditions in digital therapeutics trials risk misleading efficacy claims.
Let’s raise the bar for DTx trial design.
🔗 authors.elsevier.com/a/1l-8p,L21E...
@ecnp.eu
#DTx #MentalHealth #ClinicalTrials
We argue that poor control conditions in digital therapeutics trials risk misleading efficacy claims.
Let’s raise the bar for DTx trial design.
🔗 authors.elsevier.com/a/1l-8p,L21E...
@ecnp.eu
#DTx #MentalHealth #ClinicalTrials
It was great to present on placebo and nocebo effects in depressive and anxiety disorders in an educational update session at the ECNP Congress. Many thanks to the educational committee for inviting me! @ecnp.eu
October 14, 2025 at 2:09 PM
It was great to present on placebo and nocebo effects in depressive and anxiety disorders in an educational update session at the ECNP Congress. Many thanks to the educational committee for inviting me! @ecnp.eu
Reposted by Nathan Huneke
🎥 Two new #SFB289 #webinars are uploaded on our YouTube channel! 🎥
In September 2025, @nathanhuneke.bsky.social presented his work on placebo effects in psychiatric disorders: youtu.be/Z1pyhXSV5RE
In September 2025, @nathanhuneke.bsky.social presented his work on placebo effects in psychiatric disorders: youtu.be/Z1pyhXSV5RE
Webinar: Nathan Huneke - Toward improved understanding of placebo effects in psychiatric disorders
YouTube video by SFB-TRR 289 "Treatment Expectation"
youtu.be
October 8, 2025 at 10:29 AM
🎥 Two new #SFB289 #webinars are uploaded on our YouTube channel! 🎥
In September 2025, @nathanhuneke.bsky.social presented his work on placebo effects in psychiatric disorders: youtu.be/Z1pyhXSV5RE
In September 2025, @nathanhuneke.bsky.social presented his work on placebo effects in psychiatric disorders: youtu.be/Z1pyhXSV5RE
Great to collaborate on this with @hvansteenbergen.bsky.social! We found evidence that endogenous opioids mediate attentional broadening after receiving rewards.
Excited to share that our paper “Seeing the bigger picture: Endogenous opioids mediate attentional broadening after reward receipt” has just been published in Psychological Medicine!
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
October 2, 2025 at 6:27 PM
Great to collaborate on this with @hvansteenbergen.bsky.social! We found evidence that endogenous opioids mediate attentional broadening after receiving rewards.
Really enjoyed the opportunity to present at the SFB289 webinar!
Today's main speaker is @nathanhuneke.bsky.social who is trying to better understand placebo effects in psychiatric disorders in his research 🤯
If you missed it, don't worry, his talk will be available soon on our YouTube channel (youtube.com/@sfb-trr_289...) 🤩
If you missed it, don't worry, his talk will be available soon on our YouTube channel (youtube.com/@sfb-trr_289...) 🤩
September 3, 2025 at 8:07 PM
Really enjoyed the opportunity to present at the SFB289 webinar!
Great to be part of this
BIG PREPRINT🔬
In a newly founded consortium we show that we barely know anything about the neurobiology underlying emotion regulation capacity! (40 fmri samples, N=2175)
So, time-out for prefrontal cortex explanations!
And we also show why this might be the case 🧵
www.biorxiv.org/content/10.1...
In a newly founded consortium we show that we barely know anything about the neurobiology underlying emotion regulation capacity! (40 fmri samples, N=2175)
So, time-out for prefrontal cortex explanations!
And we also show why this might be the case 🧵
www.biorxiv.org/content/10.1...
The elusive neural signature of emotion regulation capabilities: evidence from a large-scale consortium
Cognitive reappraisal is a fundamental emotion regulation strategy for mental and physical well-being, but how its neural mechanisms relate to individual differences remains poorly understood. In a co...
www.biorxiv.org
August 22, 2025 at 3:39 PM
Great to be part of this
Reposted by Nathan Huneke
Our new study published in TheLancetPsych! We found that pramipexole augmentation substantially reduced depressive symptoms in patients with treatment-resistant depression over 48 weeks of treatment. This is an important advance in how we treat depression! 1/6
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK
In this trial involving participants with treatment-resistant depression, pramipexole
augmentation of antidepressant treatment, at a target dose of 2·5 mg, demonstrated
a reduction in symptoms relativ...
www.thelancet.com
June 30, 2025 at 3:54 AM
Our new study published in TheLancetPsych! We found that pramipexole augmentation substantially reduced depressive symptoms in patients with treatment-resistant depression over 48 weeks of treatment. This is an important advance in how we treat depression! 1/6
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Reposted by Nathan Huneke
Timely article!
May 28, 2025 at 3:40 AM
Timely article!
Our thoughts on missing data, statistics and placebo effects in psychiatric trials.
Thanks Samuele Cortese and Marco Solmi!
jamanetwork.com/journals/jam...
Thanks Samuele Cortese and Marco Solmi!
jamanetwork.com/journals/jam...
Understanding Placebo Mechanisms to Reduce Attrition in Psychiatric Trials
Placebo responses in psychiatric trials are clinically significant and variable.1 When placebo response is large, the assay sensitivity of a clinical trial can be impacted, meaning that it can potenti...
jamanetwork.com
April 16, 2025 at 3:36 PM
Our thoughts on missing data, statistics and placebo effects in psychiatric trials.
Thanks Samuele Cortese and Marco Solmi!
jamanetwork.com/journals/jam...
Thanks Samuele Cortese and Marco Solmi!
jamanetwork.com/journals/jam...
Very important initiative!
Psych-DS is (1) spellcheck for your datasets and (2) a pathway to standardizing data in our academic fields that *everyone* can learn.
And it's live RIGHT NOW!
psych-ds.github.io
(This is the announcement post I've been leading up to)
And it's live RIGHT NOW!
psych-ds.github.io
(This is the announcement post I've been leading up to)
Psych-DS
A specification for psychological datasets. JSON metadata, predictable directory structure, and machine-readable specifications for tabular datasets.
psych-ds.github.io
April 11, 2025 at 9:35 AM
Very important initiative!
Reposted by Nathan Huneke
Our new review in JAMA Psychiatry: "Expectancy Effects, Failure of Blinding Integrity, and Placebo Response in Trials of Treatments for Psychiatric Disorders"
jamanetwork.com/journals/jam...
Thanks to co-first author Guil Fusetto-Veronesi; and to Samuele Cortese, David Baldwin, Matt Garner
🧵👇
jamanetwork.com/journals/jam...
Thanks to co-first author Guil Fusetto-Veronesi; and to Samuele Cortese, David Baldwin, Matt Garner
🧵👇
Expectancy Effects, Blinding Integrity, and Placebo Response in Psychiatric Disorders
This narrative review discusses the impact of expectancy effects and functional unblinding on treatment responses in randomized clinical trials of treatments in psychiatry.
jamanetwork.com
March 12, 2025 at 5:00 PM
Our new review in JAMA Psychiatry: "Expectancy Effects, Failure of Blinding Integrity, and Placebo Response in Trials of Treatments for Psychiatric Disorders"
jamanetwork.com/journals/jam...
Thanks to co-first author Guil Fusetto-Veronesi; and to Samuele Cortese, David Baldwin, Matt Garner
🧵👇
jamanetwork.com/journals/jam...
Thanks to co-first author Guil Fusetto-Veronesi; and to Samuele Cortese, David Baldwin, Matt Garner
🧵👇
Our new review in JAMA Psychiatry: "Expectancy Effects, Failure of Blinding Integrity, and Placebo Response in Trials of Treatments for Psychiatric Disorders"
jamanetwork.com/journals/jam...
Thanks to co-first author Guil Fusetto-Veronesi; and to Samuele Cortese, David Baldwin, Matt Garner
🧵👇
jamanetwork.com/journals/jam...
Thanks to co-first author Guil Fusetto-Veronesi; and to Samuele Cortese, David Baldwin, Matt Garner
🧵👇
Expectancy Effects, Blinding Integrity, and Placebo Response in Psychiatric Disorders
This narrative review discusses the impact of expectancy effects and functional unblinding on treatment responses in randomized clinical trials of treatments in psychiatry.
jamanetwork.com
March 12, 2025 at 5:00 PM
Our new review in JAMA Psychiatry: "Expectancy Effects, Failure of Blinding Integrity, and Placebo Response in Trials of Treatments for Psychiatric Disorders"
jamanetwork.com/journals/jam...
Thanks to co-first author Guil Fusetto-Veronesi; and to Samuele Cortese, David Baldwin, Matt Garner
🧵👇
jamanetwork.com/journals/jam...
Thanks to co-first author Guil Fusetto-Veronesi; and to Samuele Cortese, David Baldwin, Matt Garner
🧵👇
Reposted by Nathan Huneke
🧠 Help Us Understand Pain Perception in FND! 🧠
Looking for volunteers with & without #FND for a study in London @kingsioppn.bsky.social. Single lab visit testing pain perception with electrical stimulation.
Interested? Please message me: [email protected] ✉️
Thanks for sharing!
Looking for volunteers with & without #FND for a study in London @kingsioppn.bsky.social. Single lab visit testing pain perception with electrical stimulation.
Interested? Please message me: [email protected] ✉️
Thanks for sharing!
March 7, 2025 at 2:13 PM
🧠 Help Us Understand Pain Perception in FND! 🧠
Looking for volunteers with & without #FND for a study in London @kingsioppn.bsky.social. Single lab visit testing pain perception with electrical stimulation.
Interested? Please message me: [email protected] ✉️
Thanks for sharing!
Looking for volunteers with & without #FND for a study in London @kingsioppn.bsky.social. Single lab visit testing pain perception with electrical stimulation.
Interested? Please message me: [email protected] ✉️
Thanks for sharing!
Reposted by Nathan Huneke
Why academia is sleepwalking into self-destruction. My editorial @brain1878.bsky.social If you agree with the sentiments please repost. It's important for all our sakes to stop the madness
academic.oup.com/brain/articl...
academic.oup.com/brain/articl...
March 6, 2025 at 7:16 PM
Why academia is sleepwalking into self-destruction. My editorial @brain1878.bsky.social If you agree with the sentiments please repost. It's important for all our sakes to stop the madness
academic.oup.com/brain/articl...
academic.oup.com/brain/articl...
Reposted by Nathan Huneke
#Pubmed problems being reported
Please say if it’s working for you, your country and search engine
(perhaps retweet for larger sample size
🤷♂️ fine for me, UK & Safari
Please say if it’s working for you, your country and search engine
(perhaps retweet for larger sample size
🤷♂️ fine for me, UK & Safari
March 2, 2025 at 7:51 AM
#Pubmed problems being reported
Please say if it’s working for you, your country and search engine
(perhaps retweet for larger sample size
🤷♂️ fine for me, UK & Safari
Please say if it’s working for you, your country and search engine
(perhaps retweet for larger sample size
🤷♂️ fine for me, UK & Safari
Pleased to be able to share our meta-analysis exploring placebo and nocebo response in gambling disorder, out now in Acta Neuropsychiatrica. This is the first meta-analysis of placebo response in RCTs for gambling disorder.
https://buff.ly/3V8dnk3
https://buff.ly/3V8dnk3
November 22, 2024 at 5:27 PM
Pleased to be able to share our meta-analysis exploring placebo and nocebo response in gambling disorder, out now in Acta Neuropsychiatrica. This is the first meta-analysis of placebo response in RCTs for gambling disorder.
https://buff.ly/3V8dnk3
https://buff.ly/3V8dnk3
Reposted by Nathan Huneke
New starter pack: Mental Health Professionals
For facts/expertise, but not individual clinical advice!
Just getting started... will add more as time goes by...
bsky.app/starter-pack...
For facts/expertise, but not individual clinical advice!
Just getting started... will add more as time goes by...
bsky.app/starter-pack...
November 17, 2024 at 12:27 AM
New starter pack: Mental Health Professionals
For facts/expertise, but not individual clinical advice!
Just getting started... will add more as time goes by...
bsky.app/starter-pack...
For facts/expertise, but not individual clinical advice!
Just getting started... will add more as time goes by...
bsky.app/starter-pack...
Reposted by Nathan Huneke
Huge congratulations to all the nominees and winners at last night’s #VCAwards2024 🏆✨
Held at St Mary’s Stadium, it was an inspiring evening recognising the dedication and talent across our University.
#WeAreUoS
Held at St Mary’s Stadium, it was an inspiring evening recognising the dedication and talent across our University.
#WeAreUoS
October 4, 2024 at 11:30 AM
Huge congratulations to all the nominees and winners at last night’s #VCAwards2024 🏆✨
Held at St Mary’s Stadium, it was an inspiring evening recognising the dedication and talent across our University.
#WeAreUoS
Held at St Mary’s Stadium, it was an inspiring evening recognising the dedication and talent across our University.
#WeAreUoS
Is there a way to search for starter packs?
October 26, 2024 at 8:21 PM
Is there a way to search for starter packs?
Trying bluesky again. Which feeds should I follow?
October 18, 2024 at 8:20 PM
Trying bluesky again. Which feeds should I follow?
Very pleased this is now available online "Placebo Effects Are Small on Average in the 7.5% CO2 Inhalational Model of Generalised Anxiety"
academic.oup.com/ijnp/advance...
🧵👇
academic.oup.com/ijnp/advance...
🧵👇
Placebo Effects Are Small on Average in the 7.5% CO2 Inhalational Model of Generalised Anxiety
AbstractBackground. Anxiety disorders are highly prevalent and socio-economically costly. Novel pharmacological treatments for these disorders are needed a
academic.oup.com
April 26, 2024 at 7:36 PM
Very pleased this is now available online "Placebo Effects Are Small on Average in the 7.5% CO2 Inhalational Model of Generalised Anxiety"
academic.oup.com/ijnp/advance...
🧵👇
academic.oup.com/ijnp/advance...
🧵👇
Excited to announce I am joining the #ECNP Early Career Academy! Looking forward to working with everyone else in the academy on applied #neuroskyence
March 29, 2024 at 12:02 PM
Excited to announce I am joining the #ECNP Early Career Academy! Looking forward to working with everyone else in the academy on applied #neuroskyence
How to define treatment resistance in anxiety disorders? Our Delphi method-based consensus is out now in World Psychiatry.
Led by Katharina Domschke and David Baldwin via the ECNP Anxiety Disorders Research Network
www.ncbi.nlm.nih.gov/pmc/articles...
Led by Katharina Domschke and David Baldwin via the ECNP Anxiety Disorders Research Network
www.ncbi.nlm.nih.gov/pmc/articles...
The definition of treatment resistance in anxiety disorders: a Delphi method‐based consensus guide...
Anxiety disorders are very prevalent and often persistent mental disorders, with a considerable rate of treatment resistance which requires regulatory clinical trials of innovative therapeutic interve...
www.ncbi.nlm.nih.gov
January 16, 2024 at 5:01 PM
How to define treatment resistance in anxiety disorders? Our Delphi method-based consensus is out now in World Psychiatry.
Led by Katharina Domschke and David Baldwin via the ECNP Anxiety Disorders Research Network
www.ncbi.nlm.nih.gov/pmc/articles...
Led by Katharina Domschke and David Baldwin via the ECNP Anxiety Disorders Research Network
www.ncbi.nlm.nih.gov/pmc/articles...